Indication
Relapsed/Refractory NUP98-r Acute Leukemia
1 clinical trial
3 products
Clinical trial
A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute LeukemiaStatus: Not yet recruiting, Estimated PCD: 2027-08-01
Product
ZiftomenibProduct
CytarabineProduct
Fludarabine